Capital Healthcare Ventures focuses on promising seed- and
early-stage investment opportunities across a broad spectrum
of the healthcare industry.
technology from leading universities and research institutions
and, in partnership with renowned researchers, industry experts
and a hand-picked team of entrepreneurs and healthcare experts,
develop and commercialize the technology, creating market-leading
science into success
abound in healthcare. Amazing scientific discoveries are helping
to prolong and improve the quality of peoples’ lives.
In the past century, more advances in medical science have
occurred than in all of human history.
the world for the better
only 100 years ago that smallpox was decimating populations.
Now it’s effectively eliminated. Some 50 years ago,
the image of a child in an iron lung gripped every worried
parent’s mind. Jonas Salk’s miracle polio vaccine
has made that a distant memory. Discoveries of penicillin
and insulin, Watson and Crick’s pioneering work with
DNA, dramatic deceases in heart disease and stroke mortality
rates, increased cancer survival rates, organ transplantation,
new treatments for mental illness, are but a few other examples
of modern medical miracles.
at the center of it all
the credit goes to some 2,000 U.S. universities that will
spend upwards of $50 billion this year alone to conduct groundbreaking
research in every facet of medical science. Advancements in
medical science have also had a critical impact on the overall
economy. Healthcare is the nation’s largest employer,
providing over 13 million jobs and generating over $1.5 trillion
wealth of opportunities
of all the remarkable progress being made in medicine, significant
needs remain for improving the diagnosis and treatment of
disease and the delivery of healthcare services. With an aging
U.S. population and the development of improved healthcare
systems worldwide the healthcare industry will continue to
mandate to work with organizations like carrot capital
to encourage continued discovery, the government passed the
“Bayh-Dole” Act, which gave universities conducting
federally funded research ownership to the intellectual property
developed under this arrangement. It had a profound effect.
The number of patents generated by universities has grown
from 250 to over 2,000 annually. The Act also mandated that
universities actively seek ways to commercialize this technology
for the public good. Most importantly, this law directed these
institutions to give licensing preferences to small businesses.
we come in
and research institutions by their very nature are chiefly
focused on basic research and discovery. Most large venture
capital funds have historically favored later-stage investments,
closer to commercialization, where less nurturing is required
and where they can deploy larger amounts of capital. Established
healthcare companies also tend to shy away from licensing
technology early, preferring to wait until it’s further
refined, usually once clinical trials and the regulatory process
are well underway.
bridging the financing gap
a “financing gap” during this translational period
from science to enterprise, creating a significant opportunity
for Carrot Capital Healthcare Ventures.
we add value
Capital Healthcare Ventures’ management team works closely
with dozens of universities and research institutions across
the U.S. to identify, evaluate and negotiate license opportunities.
Once the technology is licensed, we capitalize the business,
create high-caliber management teams, accelerate any necessary
product development and clinical work, expand the intellectual
property portfolio and product pipeline, oversee the regulatory
process, and build sales and distribution channels -- all
with the objective of creating world class healthcare companies.